Motor neurone disease: progress and challenges

Thanuja Dharmadasa, Robert D Henderson, Paul S Talman, Richard AL Macdonell, Susan Mathers, David W Schultz, Merrillee Needham, Margaret Zoing, Steve Vucic and Matthew C Kiernan
Med J Aust 2017; 206 (8): . || doi: 10.5694/mja16.01063
Published online: 1 May 2017


  • Major progress has been made over the past decade in the understanding of motor neurone disease (MND), changing the landscape of this complex disease.
  • Through identifying positive prognostic factors, new evidence-based standards of care have been established that improve patient survival, reduce burden of disease for patients and their carers, and enhance quality of life. These factors include early management of respiratory dysfunction with non-invasive ventilation, maintenance of weight and nutritional status, as well as instigation of a multidisciplinary team including neurologists, general practitioners and allied health professionals.
  • Advances in technology have enhanced our understanding of the genetic architecture of MND considerably, with implications for patients, their families and clinicians. Recognition of extra-motor involvement, particularly cognitive dysfunction, has identified a spectrum of disease from MND through to frontotemporal dementia.
  • Although riluzole remains the only disease-modifying medication available in clinical practice in Australia, several new therapies are undergoing clinical trials nationally and globally, representing a shift in treatment paradigms. Successful translation of this clinical research through growth in community funding, awareness and national MND research organisations has laid the foundation for closing the research–practice gap on this debilitating disease.
  • In this review, we highlight these recent developments, which have transformed treatment, augmented novel therapeutic platforms, and established a nexus between research and the MND community. This era of change is of significant relevance to both specialists and general practitioners who remain integral to the care of patients with MND.

  • 1 Brain and Mind Centre, University of Sydney, Sydney, NSW
  • 2 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 3 Geelong Hospital, Geelong, VIC
  • 4 University of Melbourne, Melbourne, VIC
  • 5 Calvary Health Care Bethlehem, Melbourne, VIC
  • 6 Flinders Medical Centre, Adelaide, SA
  • 7 Western Australian Neuromuscular Research Institute, Perth, WA
  • 8 Westmead Hospital, Sydney, NSW


Thanuja Dharmadasa is a recipient of an Australian Postgraduate Award (University of Sydney), a Rotary Club of Cronulla Funding Partner Scholarship, a MNDRIA PhD Top-up Grant and a Yulgilbar Foundation Alzheimer’s Research Program PhD Top-up Award. Matthew Kiernan is the Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry. This work was supported by funding to ForeFront, a collaborative research group dedicated to the study of FTD and MND, from a National Health and Medical Research Council of Australia program grant (1037746).

Competing interests:

No relevant disclosures.

  • 1. Traxinger K, Kelly C, Johnson BA, et al. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011. Neurol Clin Pract 2013; 3: 313-320.
  • 2. Kiernan MC, Talman P, Henderson RD, et al. Establishment of an Australian motor neurone disease registry. Med J Aust 2006; 184: 367-368. <MJA full text>
  • 3. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-955.
  • 4. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 639-649.
  • 5. Hobson E, Harwood C, McDermott CJ, Shaw PJ. Clinical aspects of motor neurone disease. Medicine 2016; 44(9): 552-556.
  • 6. Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci 2014; 37: 433-442.
  • 7. Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014; 10: 661-670.
  • 8. Burrell JR, Vucic S, Kiernan MC. Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011; 12: 283-289.
  • 9. Visser J, van den Berg-Vos RM, Franssen H, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 2007; 64: 522-528.
  • 10. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66: 647-653.
  • 11. Birks C, Egan M, Rizk R, et al. Motor neurone disease: aspects of care for the primary health care team. Sydney: MND Australia, 2014. (accessed Dec 2016).
  • 12. Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 2015; 86: 496-501.
  • 13. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study. J Neurol Neurosurg Psychiatry 2003; 74: 1258-1261.
  • 14. Kleopa KA, Sherman M, Neal B, et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999; 164: 82-88.
  • 15. Berlowitz DJ, Howard ME, Fiore JF, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatry 2016; 87: 280-286.
  • 16. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1218-1226.
  • 17. Corcia P, Pradat P-F, Salachas F, et al. Causes of death in a postmortem series of ALS patients. Amyotroph Lateral Scler 2008; 9: 59-62.
  • 18. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53: 1059-1063.
  • 19. Desport JC, Preux PM, Truong CT, et al. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91-96.
  • 20. Spataro R, Ficano L, Piccoli F, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci 2011; 304: 44-48.
  • 21. Wills A-M, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014; 383: 2065-2072.
  • 22. Connolly S, Galvin M, Hardiman O. End of life management in patients with amyotrophic lateral sclerosis. Lancet Neurol 2015; 14: 435-442.
  • 23. Murray L, Butow PN, White K, et al. Advance care planning in motor neuron disease: a qualitative study of caregiver perspectives. Palliative Medicine 2016; 30(5): 471-478.
  • 24. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012; 83: 102-108.
  • 25. Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet 2016; pii: S0140-6736(16) 00737-00746.
  • 26. Snowden JS, Harris J, Richardson A, et al. Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 172-176.
  • 27. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 323-330.
  • 28. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603-615.
  • 29. Gros-Louis F, Gaspar C, Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta 2006; 1762: 956-972.
  • 30. Hanby MF, Scott KM, Scotton W, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain 2011; 134: 3454-3457.
  • 31. Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016; 48: 1043-1048.
  • 32. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 2017; 19: 267-274.
  • 33. Williams KL, Fifita JA, Vucic S, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry 2013; 84: 931-935.
  • 34. Chio A, Battistini S, Calvo A, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014; 85: 478-485.
  • 35. Akimoto C, Volk AE, van Blitterswijk M, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 2014; 51: 419-424.
  • 36. McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ 2008; 336: 658-662.
  • 37. Zoing MC, Burke D, Pamphlett R, et al. Riluzole therapy for motor neurone disease: an early Australian experience (1996–2002). J Clin Neurosci 2006; 13: 78-83.
  • 38. Zoccolella S, Beghi E, Palagano G, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol 2007; 14: 262-268.
  • 39. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; (3): CD001447.
  • 40. Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006; 12: 9-20.
  • 41. Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 610-617.
  • 42. Kaji R, Kuzuhara S, Iwasaki Y, et al. Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS: report of 7 years’ randomised double-blind, phase 3 clinical trial ( NCT00444613). Neurology 2015; 84 (Suppl): 7060.
  • 43. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009; 4: e7258.
  • 44. Williams JR, Trias E, Beilby PR, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the copper-chaperone-for-SOD. Neurobiol Dis 2016; 89: 1-9.
  • 45. Li W, Lee M-H, Henderson L, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med 2015; 7: 307ra153.
  • 46. Meotti FC, Lemos AE, Calixto JB. TRP modulation by natural compounds. Handb Exp Pharmacol 2014; 223: 1177-1238.
  • 47. Scarrott JM, Herranz-Martín S, Alrafiah AR, et al. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther 2015; 15: 935-947.
  • 48. Lunn JS, Sakowski SA, Feldman EL. Concise review: stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells 2014; 32: 1099-1109.
  • 49. Richard JP, Maragakis NJ. Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res 2014; 1607: 15-25.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.